CASE-BASED ROUNDTABLE

Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.

Latest Articles

Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices

Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices

September 28, 2026

Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.

Evaluating Platelet- vs Immune-Directed Therapies in Immune Thrombocytopenia

Evaluating Platelet- vs Immune-Directed Therapies in Immune Thrombocytopenia

September 21, 2026

During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.

Navigating the Next Step After Progression in ccRCC

Navigating the Next Step After Progression in ccRCC

September 18, 2026

Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.

Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma

Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma

September 17, 2026

During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.

After the First ADC Fails, HR-Positive Breast Cancer Sequencing Runs on Judgment, Not Trial Data

After the First ADC Fails, HR-Positive Breast Cancer Sequencing Runs on Judgment, Not Trial Data

September 16, 2026

During a live event, Ruta Rao, MD, and participants discussed how toxicity history, rather than head-to-head trial data, drives the choice among 3 antibody-drug conjugates once the first one fails or becomes intolerable.

Adverse Event Burden Tips TKI Selection in Recurrent Diffuse TGCT

Adverse Event Burden Tips TKI Selection in Recurrent Diffuse TGCT

September 11, 2026

During a live event, Seth M. Pollack, MD, and participants discussed how the practical burden of toxicity monitoring is increasingly steering the choice between systemic therapies for recurrent diffuse tenosynovial giant cell tumor.

Dosing and Toxicity Considerations for Heavily Pretreated Patients With Myeloma

Dosing and Toxicity Considerations for Heavily Pretreated Patients With Myeloma

September 09, 2026

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.

Reactive, Lineage-by-Lineage Care Still Defines Anemia and Thrombocytopenia Management in ES-SCLC

Reactive, Lineage-by-Lineage Care Still Defines Anemia and Thrombocytopenia Management in ES-SCLC

September 08, 2026

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how anemia and thrombocytopenia in extensive-stage small cell lung cancer are still managed one lineage, and one crisis, at a time.

Thinking Beyond Efficacy When Selecting BTK Inhibitors in Relapsed CLL

Thinking Beyond Efficacy When Selecting BTK Inhibitors in Relapsed CLL

September 03, 2026

Clinicians weigh acalabrutinib vs zanubrutinib for relapsed CLL, focusing on adverse effects, trial data, and where pirtobrutinib fits next.

G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC

G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC

September 02, 2026

During a virtual event, Eric K. Singhi, MD, and participants discussed how the ROS1 G2032R resistance mutation is guiding second-line therapy selection in ROS1-positive advanced non–small cell lung cancer.

Strategies Shift Beyond Traditional Management of Immune Thrombocytopenia

Strategies Shift Beyond Traditional Management of Immune Thrombocytopenia

August 28, 2026

Adam Cuker, MD, MS, and Amit R. Mehta, MD, discuss the changing treatment landscape and patients goals when treating chronic immune thrombocytopenia.

White Blood Cell Count May Help Refine Risk Assessment in Polycythemia Vera

White Blood Cell Count May Help Refine Risk Assessment in Polycythemia Vera

August 28, 2026

During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk assessment for polycythemia vera.

Oncologists Weigh Frontline BTK Inhibitor Strategies in CLL

Oncologists Weigh Frontline BTK Inhibitor Strategies in CLL

August 21, 2026

Experts weigh continuous vs time‑limited CLL therapy, compare acalabrutinib and zanubrutinib, and debate when pirtobrutinib fits first line.

Bridging Before CAR T in Myeloma Should Aim For Deep Response, Not Just Stability

Bridging Before CAR T in Myeloma Should Aim For Deep Response, Not Just Stability

August 20, 2026

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed how aggressively to bridge a CAR T-eligible patient with high-risk relapsed myeloma.

Oncologists Weigh Patient Goals, AEs, and Cost in Treating Low-Volume mHSPC

Oncologists Weigh Patient Goals, AEs, and Cost in Treating Low-Volume mHSPC

August 19, 2026

During a Community Case Forum event, Manojkumar Bupathi, MD, MS, and participants discussed how drug interactions, cost, and day-to-day tolerability are what separate one ARPI regimen from another in hormone-sensitive prostate cancer.

View a specific disease type